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Tuberculosis (TB) is a huge global burden, with new and resistant strains emerging at an alarming
rate, necessitating an urgent need for a new class of drug candidates. Here, we report that SL3, a
novel 33-amino acid peptide, causes debilitating effects on mycobacterial morphology. Treatment
with SL3 drastically inhibits the growth of Mycobacterium tuberculosis in vitro as well as in a pre-
clinical mouse model for M.tb infection. Microarray analysis of SL3-expressing strain demonstrates
wide-scale transcriptional disruption in M.tb. We therefore believe that SL3 and similar peptides
may herald a new approach towards discovering new molecules for TB therapy.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Mycobacterium tuberculosis is remarkably skillful in surviving
inside host macrophages and altering the macrophagial gene
expression for its own beneﬁt. This involves an intricate network-
ing of crucial protein–protein interactions [1–3]. One interesting
approach for combating tuberculosis is to target mycobacterial
proteins and virulence factors [4]. One key protein in mycobacte-
rial pathogenesis is the virulence determinant protein ESAT-6 that
is encoded by region of difference 1 (RD1), the region absent from
Bacillus Calmette–Guérin (BCG) and many attenuated strains of
M.tb [5–8]. The 9.5 kb RD1 encodes for ESAT-6, its cognate binder
CFP10, and a secretion system [9]. ESAT-6 is a potent human T cell
antigen and a putative vaccine candidate that also contributes to
virulence, mediates cellular cytolysis, and inhibits immune
response by host cells [10,11]. In addition, ESAT-6 reduces theantigen presenting efﬁciency of macrophages by decreasing
IFN-c induced expression of MHC class II [12]. Due to its helix-
turn-helix structure and hydrophobic nature, ESAT-6 possesses
membrane lytic activity, an attribute that helps mycobacteria
escape phagolysosome and disperse [13]. Additionally, ESAT-6
has also been postulated to play a role in macrophagial aggregation
and granuloma formation [14]. Impeding ESAT-6 and its interac-
tions may therefore provide anti-tubercular therapeutics.
ESAT-6 forms a 1:1 heterodimeric complex with CFP10 and,
once secreted, dissociates under phagosomal acidic conditions
[15,16]. Previously, we had shown that a 33 amino acid peptide,
SL3, isolated from lung cDNA library, binds ESAT6 potently [17].
Our aim was to sequester free ESAT-6 such that it is rendered inca-
pable in performing its functions. We report here that SL3 (amino
acid sequence: AAARIRHEGVFLLIGNSCFSLPRNGPQLLLLAW⁄), both
exogenously and endogenously, causes debilitating effects on
mycobacterial morphology and extra-as well as intracellular
growth. Effects of SL3 were also studied in a mouse model of TB.
We observed that SL3 led to an accelerated clearance of M.tb from
lungs and spleen. We therefore believe that the present study
opens up a new path for peptide-based anti-TB therapeutics and
merits further exploration.
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2.1. Effect of SL3 on in vitro growth
M.tb strains H37Rv/SL3 (expressing SL3-His6X endogenously;
cloning described in Supplementary information), H37Rv/pVV16
(possessing only the plasmid control), DRD1 (RD1-deﬁcient
H37Rv mutant), H37Rv + SL3 (SL3 peptide added exogenously to
mycobacterial cultures) and H37Rv + DMSO (vehicle control) were
inoculated in triplicates in vitro and growth recorded spectropho-
tometrically for 18 days at 630 nm as described earlier [18]. SL3-
His6X peptide (GenScript, Hong Kong) was added to 7H9 medium
exogenously (H37Rv + SL3) at a ﬁnal concentration of 10 lg/ml.
DRD1, H37Rv + DL1 (addition of an unrelated peptide at same con-
centration; sequence provided in Supplementary Fig. 1a) and
H37Rv + DMSO (addition of equivalent amount of DMSO, used to
dissolve SL3-His6X peptide) were used as controls. Due to precipi-
tation of the peptide SL3-His6X at concentrations >10 lg/ml, higher
concentrations could not be used. Another ESAT6 binding peptide,
HCL2 – part of a separate study, was also analyzed for its effects on
mycobacterial growth during this experiment (unpublished
results).
2.2. Electron microscopy and colony morphology
Effects of SL3 on M.tb cellular morphology was determined by
Transmission Electron Microscopy as described earlier [18]. Colony
morphology of H37Rv/SL3 strain was also observed and compared
with control H37Rv. Photographs of representative colonies were
taken using a Panasonic 14 Megapixel Camera.
2.3. Infection of THP-1 cells by M. tuberculosis in presence of SL3
peptide
A previously described experimental protocol [19] has been
briefed in Supplementary information. For intracellular survival
studies, the ESAT-6 binder HCL2 – part of a separate study – was
analyzed alongside (unpublished results).
2.4. In vivo immune response studies
2.4.1. Mice
BALB/c female mice at 6–8 weeks of age were used throughout
this study following institutional ethical committee guidelines. All
animal experiments were conducted in accordance with guidelines
approved by the Institutional Animals Ethics Committee of ICGEB,
New Delhi, India and Department of Biotechnology (DBT), Govern-
ment of India, also speciﬁcally approved the study. Mice were
housed under barrier conditions in a Biosafety Level III laboratory.
BALB/c mice were infected with 110 CFU of H37Rv and H37Rv/
SL3 using an aerosol chamber. Mice were sacriﬁced at different
time points and cytokine proﬁle and T lymphocytes proliferation
were assessed as described earlier [20]. For CFU counts lung and
spleen were harvested at different time points and processed as
described previously [20].
2.5. Total RNA isolation and microarray analysis
Total RNA was isolated using a protocol described previously
[21] as detailed in Supplementary information. Custom H37Rv
8x15k array designed by iLifediscoveries Ltd. (Agilent microarray
design identiﬁers [AMADID] 033693; Agilent) were used with
two-color labeling and oligonucleotide probe length of 60mers.
The total number of probes used was 15,744. Hybridization was
carried out for 16 h, at 10 rpm and 65 C. Agilent DNA Microarray
Scanner was used for scanning. Microarray results were veriﬁedby using RT-PCR analysis, as described in Supplementary
information.
2.6. Statistical analysis
All experiments were repeated thrice and in triplicates. Mean
values were calculated with standard deviation (STDEV) unless sta-
ted otherwise. Student’s T-test was performed to compare two
groups; p < 0.05 was considered signiﬁcant.3. Results
3.1. Endogenous expression of SL3 shows bacteriocidal effects
The expression of SL3 peptide was conﬁrmed by C-terminal
GFP-tag fusion (pVVGFPHis6X) inside M.tb H37Rv cells followed
by ﬂuorescence microscopy (Fig. 1a). A signiﬁcant decrease was
observed in mycobacterial growth in the presence of SL3. Endoge-
nously expressed peptide reduced the growth by as much as 45%
(indicated by blue dotted line) (Fig. 1b), thus indicating the anti-
mycobacterial nature of SL3. H37Rv/pVV16, H37Rv/GFP and DRD1
controls displayed the normal growth pattern. As indicated by
the electron micrographs in Fig. 1c, M.tb H37Rv/SL3 cells showed
clear disintegration of mycobacterial cell wall and change in cell
shape (indicated by arrows). Moreover, H37Rv/SL3 colony mor-
phology appeared smooth as compared with control H37Rv
(Fig. 1d). Cellular and colony morphology studies on SL3 express-
ing H37Rv suggested that, in addition to ESAT-6, SL3 might also
be involved in binding to other cytoplasmic and cell wall proteins.
In addition, intracellular survival of H37Rv/SL3 inside THP-1 cells
was drastically reduced after 72 h as compared with control strains
H37Rv/pVV16, H37Rv/GFP and DRD1 (Fig. 1e), suggesting potential
SL3 activity on phagocytosed bacteria.
3.2. SL3 induces bacterial killing
A major limitation in the development of new drugs against
M.tb is the entry of the molecule through the mycolic acid cell wall
so as to reach its target, making the screening for new antimyco-
bacterial compounds an arduous and stringent exercise [22].
ESAT-6, however, is a secretory protein and SL3 does not need to
penetrate the cell wall in order to reach its target. Moreover, the
bacteriocidal potential of SL3 remained unchanged when adminis-
tered exogenously. A 30% (in comparison to vehicle/DMSO control;
blue dotted line) and 46% (in comparison to wt H37Rv; red dotted
line) reduction in growth was observed when SL3 was added to
M.tb culture media, while H37Rv + DL1 showed uninterrupted
growth and H37Rv + DMSO demonstrated minor dip in growth
due to DMSO (Fig. 2a). Similarly, CFU counts for studies where
SL3 was added exogenously showed a drastic reduction in M.tb
intracellular survival (Fig. 2b). Any possible cytotoxic effects of
SL3 on THP-1 cells were studied by MTT assay at 0, 24, 48 and
72 h after addition of 10 lg/ml SL3 peptide. No cytotoxicity was
observed (data not shown). It should also be pointed out that in
presence of exogenous SL3, H37Rv + SL3 cells appeared completely
devoid of cell wall (indicated by arrows) (Fig. 2c).
3.3. M. tuberculosis H37Rv/SL3 establish infection
We observed a signiﬁcant reduction in bacterial burden in ani-
mals that were infected with H37Rv/SL3 compared with that of
control H37Rv infected animals. A complete clearance of M.tb
was registered within 10–12 days post-infection (data not shown).
We further analyzed immunological parameters in these animals.
At 10 days post-infection, in vivo proliferation of immune cells
Fig. 1. Endogenous expression of SL3 shows bacteriocidal effects. (a) Expression of peptide SL3-His6X in H37Rv cells. (b) Signiﬁcant reduction was observed in mycobacterial
growth in the presence of endogenous SL3. Growth reduction was found to be statistically signiﬁcant (Student’s T-test, ⁄p < 0.05). (c) Transmission electron micrographs of
mycobacterial cells showing effects of endogenous SL3 on cell wall integrity and cell shape. (d) Representative colony images depicting change in colony surface.
(e) Signiﬁcant reduction was found in mycobacterial count inside THP-1 cells in the presence of endogenous SL3. All experiments were conducted in triplicates and repeated
at least thrice. (t = 0) Deﬁnes the time at the beginning of phagocytosis. All readings were found to be statistically signiﬁcant by applying Student’s T-test (⁄p < 0.05).
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numbers of CD4, NK1.1 and Sca1+ were reduced compared to con-
trol animals that were infected with H37Rv (Supplementary
Fig. 1b). However, there was no signiﬁcant difference with regard
to CD8+ T cells (Supplementary Fig. 1b). CD11B and CD11C levels
were found to be higher in H37Rv/SL3 infected mice as compared
to control mice (Supplementary Fig. 1b). At 10 days post-infection,
reduced Alveolar cell proliferation and CD4+ T cell proliferation
was observed in whole lung T cells by BrdU incorporation in
H37Rv/SL3 infected mice (Supplementary Fig. 1c and d). CD69
expression in CD4+ T cell populations was assessed to determine
the early activation of T helper subset and a signiﬁcantly lower
expression was found in case of mice infected with H37Rv/SL3
(Supplementary Fig. 1e). To check for possible SL3 cytotoxicity in
host cells we performed the viability test in mice lung lympho-
cytes. No toxicity was observed (Supplementary Fig. 2a). To check
the status of regulatory T cells in lungs of H37Rv/SL3 infected mice,
we gated CD4+CD25+ T cells and studied the percentage of FoxP3
expression and found lowered regulatory T cells as compared to
control mice (Supplementary Fig. 2b).
To check the cytokine milieu in H37Rv/SL3 and H37Rv infected
mice, we isolated the cells from lungs and cultured them with
Phorbol-12-myristate-13-acetate (PMA), Ionomycin and M.tb
lysate/complete soluble antigen (CSA) in appropriate concentra-
tions overnight. Subsequently, after 6 h of Brefeldin A (BFA)
treatment, we carried out intracellular staining for IL-4, IFN-c,
IL-17, IL-9, IL-12, TNF-a, IL-6, TGF-b and IL-22. We found nodifference in IL-22 and TNF-a, but obtained a signiﬁcant downreg-
ulation of IL-4, IFN-c, IL-17, IL-9, IL-12, IL-6 and TGF-b secretion in
H37Rv/SL3 infected mice (Supplementary Fig. 2c). Almost all the
immune parameters, irrespective of their types, were reduced in
H37Rv/SL3 infected animals suggesting that the strain is poorly
immunogenic, which might be because of faster depletion of anti-
gens. Nonetheless, it is clear that introduction of such a peptide
imparts anti-mycobacterial activities by accelerated antigen clear-
ance and cell wall disintegration even though it possesses little or
no immunomodulatory activity.
3.4. Effect of SL3 on global gene proﬁle of M. tuberculosis
Microarray experiments were performed to study the effects of
SL3 on mycobacterial growth and cellular morphology. To identify
the genes that were differentially expressed in presence of SL3,
gene expression proﬁles of M.tb expressing SL3 (H37Rv/SL3) and
wild type H37Rv were compared. Genes having a fold change
>1.5 and a p value <0.05 were considered signiﬁcant. Detailed
results have been deposited at NCBI’s Gene Expression Omnibus
[23] and are accessible through GEO: GSE51085 (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE51085).
We found differential expression of 1025 genes, of which 716
were found to be signiﬁcantly upregulated and 309 genes signiﬁ-
cantly downregulated (please see Supplementary Fig. 3a). The dif-
ferentially expressed genes were compared with the known
essential genes for in vitro growth as well as growth within
Fig. 2. SL3 peptide addition induces bacterial killing. (a) Signiﬁcant reduction was observed in mycobacterial growth in the presence of exogenous SL3. Growth reduction was
found to be statistically signiﬁcant (Student’s T-test, ⁄p < 0.05). (b) Signiﬁcant reduction was found in mycobacterial count inside THP-1 cells in the presence of exogenous SL3
added to RPMI media. All experiments were conducted in triplicates and repeated at least thrice. (t = 0) deﬁnes the time at the beginning of phagocytosis. All readings were
found statistically signiﬁcant by applying Student’s T-test (⁄p < 0.05). (c) Transmission electron micrographs of mycobacterial cells showing effects of exogenous SL3 on cell
wall integrity and cell shape (indicated by arrows).
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[24,25]. Out of the 716 upregulated genes, 125 were found to be
essential for mycobacterial growth and survival while 2 were
essential as well as involved in ESX1 secretion system (Fig. 3a).
On the other hand, out of the 309 downregulated genes, 83 were
found to be essential for mycobacterial growth and survival, 2 were
involved in ESX1 secretion system while 2 were essential as well as
involved in ESX1 secretion system (Fig. 3b). Detailed lists for genes
in each subset of Venn diagram have been provided in Supplemen-
tary Table 1. Out of the 127 upregulated essential genes, 64 genes
code for uncharacterized and putative proteins, 32 for bacterial
metabolism, 4 for ribosomal proteins, 8 are involved in mycobacte-
rial biosynthetic pathways, 2 in mycobacterial secretion system, 2
chaperones and various other proteins involved in t-RNA synthesis,
translation and transcriptional regulation, 3 in DNA repair, con-
served membrane proteins and transporters. Essential genes that
were downregulated contain 33 putative and uncharacterized
genes, 2 genes coding for bacterial biosynthetic pathways, 2 coding
for gyrase and helicases, 5 for ribosomal proteins, 17 for enzymes
involved in bacterial metabolism, 7 genes are involved in mycobac-
terial secretion system, 4 code for proteins that are part of the pro-
teosomal degradation system, 5 are involved in oxidative
phosphorylation, 2 for chaperones and other proteins involved in
t-RNA synthesis, translation, transcription, DNA replication and
repair (Supplementary Table 1).
3.5. Quantitative PCR
To validate our microarray results, we carried out real time PCR
analysis of some of the identiﬁed genes. The genes chosen for suchanalysis were acpM (Rv2244) and cfp10 (Rv3874). The 16S rRNA
gene was used as an internal control to compare the relative
expression levels of these genes between treated (H37Rv/SL3) and
control (H37Rv/pVV16) samples. Both the genes showed corre-
sponding fold change values in RT-PCR experiment comparable
to microarray results (Supplementary Fig. 3b). acpM and cfp10
demonstrated fold change values of 1.81 and 1.91 respectively
in microarray experiment.
4. Discussion
ESAT-6 is a potent virulence determinant and an ideal target
molecule to combat TB [10,13,14,26,27,11]. Previously, we
reported that SL3, a short fragment from human lung cDNA library,
interacts strongly with ESAT-6 possibly through hydrophobic
interactions, such that even CFP10, the natural partner of ESAT-6
is not able to displace SL3 once the latter is bound to ESAT-6 [17].
In the present study, we have shown that SL3 inhibits the
growth of M.tb in axenic cultures. We used two approaches to
investigate the effect of SL3: endogenous expression and exoge-
nous addition of the peptide to growing cultures. Growth curve
analysis revealed a signiﬁcant reduction in mycobacterial growth
under both conditions. As demonstrated in our previous studies
[18], ESAT-6 binders interfere with cellular morphology and cell
integrity of the bacteria. In agreement with this, our electron
microscopy data showed distinct alteration in cell morphology
(Fig. 1c and 2c). Likewise, mycobacteria expressing SL3 formed a
distinctly smoothened colony. However, expression or addition of
SL3 to Escherichia coli cultures had no effect on bacterial growth
and cellular integrity (data not shown). These results could be
Fig. 3. SL3 alters M. tuberculosis gene expression proﬁle. (a) Comparison with
Rubin’s lists and a list of ESX1 secretion system associated genes with genes that
were found to be upregulated in microarray experiments. (b) Comparison with
Rubin’s lists and ESX1 secretion system associated genes with genes that were
found to be downregulated in microarray experiments.
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biosynthetic pathways, leading to observed morphological defects
brought about by the presence of SL3. Furthermore, SL3 addition to
Mycobacterium smeg culture did not show any signiﬁcant differ-
ences in growth pattern during the onset of log phase with some
growth deprivation in late growth and stationary phase (Supple-
mentary Fig. 3c). As previously hypothesized, proteins secreted
by ESX-1 system of M. smeg might coat the bacterial cell surface
thereby interfering with formation of speciﬁc cell–cell contacts
[28]. It appears that M. smeg ESX-1 system ascertains a prominent
role in the late log phase/early stationary phase, which is when the
suppressive role of SL3 peptide on M. smeg is realized. However,
this correlation requires better understanding of the working
mechanism as well as role of M. smeg ESX-1 system that we are
lacking currently. As M.tb is an intracellular pathogen, it is impor-
tant to validate anti-mycobacterial activity of SL3 on the phagocy-
tosed pathogen inside host macrophagial cells. We found that SL3
hinders survival of the M.tb inside human macrophagial THP-1
cells (Figs. 1e and 2b).
These results provided a basis for studying the anti-tubercular
effects of SL3 in a preclinical mouse model system. We examinedthe mycobacterial survival and immune response in BALB/c mice
infected with mycobacteria expressing SL3. Remarkably, SL3
expressing strain was cleared rapidly leading to antigenic loss as
evident by the lack of immune response activation. We found
reduced numbers of CD4, NK1.1 and Sca1+ and lowered CD69
expression in CD4+ populations in H37Rv/SL3 infected mice. SL3
was found to be non-toxic in mice lung lymphocytes and a lowered
Treg cell population conﬁrmed that lack of immune response is not
because of regulatory T cells. A similar downregulation was
observed in the protective cytokine production in H37Rv/SL3
infected mice. These data suggests that the expression of SL3 in
H37Rv attenuates its virulence and reduces its ability to mount
an immune response comparable to that of the virulent H37Rv
strain due to early clearance of H37Rv/SL3 strain.
The results were initially intriguing, since ESAT-6 is not one of
the factors that control mycobacterial growth [27]. Microarray
analysis was performed to screen differentially expressed genes
in the presence of SL3. We found differential expression of 1025
genes, of which 716 were signiﬁcantly upregulated and 309 genes
signiﬁcantly downregulated (Supplementary Fig. 3a). Previous
studies have identiﬁed sets of genes essential for in vitro growth
of M.tb as well as for survival within macrophages [24,25]. We
found a number of crucial mycobacterial genes upregulated in
the presence of SL3, including genes coding for metabolic enzymes
like Rv0118c, cysN/cysC, Rv1338, Rv2996c, Rv3540c, chaperones
and DNA repair enzymes (clpB, dnaJ 2, Exodeoxyribonuclease III,
Uracil-DNA and UvrD/Rep helicase). Importantly, we found that
SL3 expression led to upregulation of mycobacterial peptidoglycan
and mycolyl-arabinogalactan-peptidoglycan complex biosynthesis
pathways (aftA and Glycosyl transferase genes, mycolyl-arabino-
galactan–peptidoglycan complex biosynthesis genes, Rv2981c,
Rv2153c and Rv2155), in addition to mycolate biosynthesis path-
way (PCAA). This upregulation in the biosynthesis of cell wall com-
ponents can be correlated with the electron-micrographs. M.tb
affected by SL3 appears to be compensating for the loss of cell wall
by making these components in excess. Similar observations have
been made earlier with Staphylococcus aureus in response to cell
wall-active antibiotics [29]. SL3 also upregulated integral mem-
brane protein genes responsible for aminoglycosides/tetracycline-
transport, as also EspA, that is essential forM.tb growth and associ-
ated with the ESX-1 secretion system [30]. Furthermore, we also
found several genes downregulated, including genes coding for
metabolic enzymes like rfbA, fadD30, hemC, ribA2, pgk, Transketol-
ase Tkt, acn, hisC1, hisB, ACPM, pyrH, 2 genes involved in mycolic
acid biosynthesis (Rv2361c and glfT1) and to our surprise, genes
coding for proteins involved in DNA replication like gyrB, dnaB
(Rv0058) and polA (Rv1629). This could be the reason behind the
growth inhibition in the presence of SL3. SL3 also affected expres-
sion of factors involved in protein synthesis or translation, like the
elongation factor Tuf, initiation factor InfC, translation initiation
factor InfB, and initiation factor InfA, an observation that might
explain the altered cellular and colony morphology of mutant
M.tb. The major effect of SL3 seemed to be on secretion pathways
of M.tb. SL3 expression repressed the genes coding for Rv1410c,
TatC and Rv3921c proteins from the bacterial secretion system;
EccA1 and PPE68 (essential for growth and associated with ESX1
secretion system); and EspF and ESAT-6 cognate binder CFP10
(non-essential but associated with ESX1 secretion system). Micro-
array data suggests that SL3 could hinder expression and secretion
of crucial mycobacterial proteins that might be responsible for
reduced pathogenesis of H37Rv. However, whereas SL3 showed
adverse effects on the growth of M.tb, it had no visible effect on
the growth of E. coli, strengthening our belief that SL3 is interacting
with molecule(s) speciﬁc to the mycobacterial cell.
In conclusion, this study demonstrates adverse effects of SL3 on
in vitro as well as in vivo growth and pathogenesis of M.tb, and
740 S.K. Samuchiwal et al. / FEBS Open Bio 4 (2014) 735–740concomitant lack of immune response. We believe that this study,
that demonstrates the ability of a novel peptide to affect major
mycobacterial cellular processes, will provide the basis for further
exploration of SL3 functions and its implications in designing a
host of peptide-based inhibitors against M.tb.
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